2Douillard JY,Sobrero A,CarnaghiC,et al.Metastatic colorectal cancer:integrating irinotecan in combination and sequential chem-otherapy[J].Ann Oncol,2003,14(Suppl2):7-12.
3Saltz LB,Cox JV,Blanke C,et al.Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer[J].N Engl J Med,2000,343(13):905-914.
4Douillard JY,Cunningham D,Roth AD,et al.Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer:a multicentre randomised trial[J].Lancet,2000,355(9209):1041-1047.
5Colucci G,Gebbia V,Paoletti G,et al.PhaseⅢrandomized trial of FOLFIRI versus FOLFOX4in the treatment of advanced colorectal cancer:a multicenter study of the Gruppo Oncologico Dell'Italia Me-ridionale[J].J Clin Oncol,2005,23(22):4811-4814.
6Ando Y,Saka H,Ando M,et al.Polymorphisms of UDP-Glucuro-nosyl transferase gene and irinotecan toxicity:A pharmacogenetic a-nalysis[J].Cancer Res,2000,60(24):6921-6926.
7Luis P,Eve P,Laura AC,et al.Utility of pretreatment bilirubin level and UGT1A1polymorphisms in multivariate predictive models of neutropenia associated with irinotecan treatment in previously un-treated patients with colorectal cancer[J].Arch Drug Inf,2008,1(3):97-106.
